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Recently, amplification of MLL/11q23 gene has been 
reported as another recurrent amplified gene in myeloid 
malignancy. It is mainly associated with elderly 
patients, often dysplastic bone marrow, and complex 
karyotypic abnormalities. It is suggested that MLL gain 
of function is the mechanism that contributes to the 
rapid progression and dismal outcome of this leukemia. 
 
FISH using the LSI MLL breakapart probe (Vysis, Inc) showing 
MLL gene amplification in acute myeloid leukemia. 
Clinics and pathology 
Disease 
De novo acute myeloid leukemia (AML), de novo  
myelodysplastic syndromes (MDS), therapy-related 
AML, therapy-related MDS, and AML transforming 
from MDS. 
Phenotype/cell stem origin 
Generally patients presented with anemia, low platelets, 
and often leukocytosis. AML are most often FAB 
subtypes M4 and M5 (particularly M5a), followed by 
M1, M2. MDS are mostly RAEB showing multilineage 
dysplasia. The leukemic cells are positive for CD45, 
CD13, CD15, CD33, CD34, HLA-DR. 
Epidemiology 
The exact incidence of MLL amplification in myeloid 
malignancies is difficult to establish. In large studies, 
MLL amplification has been found in < 1% of 
AML/MDS with abnormal karyotype. Amplification of 
MLL gene is the second most amplified gene in 
AML/MDS after CMYC oncogene. In one study, MLL 
amplification was found in 8/27 (29%) AML cases 
exhibiting homogenously staining region (hsr) and 
double minutes (dmin). 
AML/MDS with MLL amplification is associated with 
an elderly age, a median age at presentation of 72 
years, ranged from 4 to 91 years, often prior history of 
therapy with alkylating agents or topoisomerase II, and 
slight female predominance. In therapy-related 
MDS/AML amplification of MLL gene was found in 
12% patients. 
Prognosis 
Generally, leukemia with MLL amplification is 
associated with an aggressive clinical course with poor 
response to chemotherapy, and extremely short 
survival. The median survival of the patients with 
available data is 2-3 months. 
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Cytogenetics 
Cytogenetics morphological 
MLL amplification appears in variable cytogenetics 
manifestations including hsr, dmin, ring chromosome, 
derivative 11q, and marker chromosome. 
Cytogenetics molecular 
FISH has been useful in detecting MLL amplification. 
In many cases, the MLL amplification was suspected 
by conventional banded chromosomes, but was 
confirmed by FISH instead. Most cases are identified 
on the basis of multiple MLL signals by FISH. The 
number of copies of MLL is quit variable ranging from 
5 to 90 copies per cell, and Southern blot analysis 
reveals a germline configuration of the amplified MLL 
gene in majority of cases. Simultaneous amplification 
of MLL and CMYC oncogenes on different 
chromosomal regions has been reported in at least two 
cases. 
Additional anomalies 
The majority of patients with MLL amplifications have 
complex aberrant karyotype, often hypodiploid; over 
50% of them have five or more chromosomal 
abnormalities. No patient with normal karyotype was 
found. Recurrent chromosomal abnormalities seen in 
association with MLL/11q amplifications are -5/5q-, -
7/7q-, -17/17p-, -18/18q-, and missing or structural 
abnormality of 11q. As determined by chromosome 
analysis, deletion of 5/5q and 17/17p are seen in 
approximately 80% and 50% respectively in 
AML/MDS cases exhibiting MLL amplification. 
Genes involved and proteins 
Note 
Generally MLL amplification is not associated with 
rearrangement of this gene. RNA overexpression is the 
result of the increase copy number of MLL (gain of 
function). Moreover, the amplified region is not limited 
to the MLL/11q23.3 gene locus, and other genes in the 
MLL flanking region have been also amplified. FISH 
and other molecular techniques have identified genes at 
11q such as DDX6, GAB2, ETS1, FLI1, SNX19 and/or 
NFRKB being co-amplified. The size and number of 
amplicons are variable and at least 9 regions have been 
identified at 11q23-q25. 
In addition, over 90% of AML/MDS cases with MLL 
amplification show an inactivation of TP53 by deletion 
or mutation indicating that functional TP53 loss is an 
important key alteration in this leukemia. 




MLL is homologous to the transcriptional regulator 
Drosophila trithorax (trx) protein, which is involved in 
the regulation of HOX gene expression. MLL plays an 
essential role in embryonic development, also as 
regulator of growth of hematopoietic precursors. 
To be noted 
Case Report 
Amplification of MLL gene in a new case of acute 
myeloid leukemia 
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